Posted by Michael Wonder on 02 Aug 2017
FDA approves treatment for chronic graft versus host disease
2 August 2017 - The U.S. FDA today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease after failure of one or more treatments.
This is the first FDA approved therapy for the treatment of chronic graft versus host disease
The FDA granted this application priority review and breakthrough therapy designations. Imbruvica also received orphan drug designation for this indication, which provides incentives to assist and encourage the development of drugs for rare diseases.
